<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2019.93013</article-id><article-id pub-id-type="publisher-id">WJCR-31432</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20190300000_25556959.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  CARM1通过调控Bax/Bcl-2表达和Caspase-3活性进而调控肝癌生长作用
  CARM1 Regulates the Growth of Hepatocellular Carcinoma Cells via Regulation of Bax/Bcl-2 Level and Caspase-3 Activity
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>美玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>洪</surname><given-names>宏海</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>征</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>广州医科大学附属第三医院检验科，广东 广州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>25</day><month>07</month><year>2019</year></pub-date><volume>09</volume><issue>03</issue><fpage>90</fpage><lpage>97</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：共激活因子相关精氨酸甲基转移酶1 (Coactivator-associated arginine methyltransferase 1, CARM1)在肝癌细胞中生长作用及机制研究。方法：qRT-PCR、western blot法检测肝癌细胞中CARM1表达；MTT法和台盼蓝实验检测肝癌细胞的生长情况；Caspase-3试剂盒检测Caspase-3活性；小分子干扰RNA干扰CARM1研究其作用和分子机制。结果：小分子干扰RNA明显敲低CARM1水平；干扰CARM1后明显抑制肝癌细胞生长，且下调抑凋亡蛋白Bcl-2和上调促凋亡蛋白Bax表达水平，同时激活Caspase-3活性。结论：CARM1通过调控Bax/Bcl-2表达和Caspase-3活性进而调控肝癌生长作用。
    Objective: To investigate the effect and mechanism of CARM1 on the growth of HCC. Methods: qRT-PCR and western blot were used to detect the expression of CARM1. MTT assay and Trypan blue assay were used to detect the growth of hepatocellular carcinoma cells; Caspase-3 kit was used to detect the activity of Caspase-3; small interfering RNA interference CARM1 was used to study its role and molecular mechanism on HCC growth. Results: Small interfering RNA significantly knocked down the level of CARM1; interfering with CARM1 significantly, which inhibited the growth of hepatocellular carcinoma cells, down-regulated Bcl-2, up-regulated Bax expression, and activated Caspase-3 activity. Conclusion: CARM1 regulates the growth of hepatocellular carcinoma by regulating the expression of Bax/Bcl-2 and the activity of Caspase-3. 
  
 
</p></abstract><kwd-group><kwd>肝癌，CARM1，Bcl-2，Bax，Caspase-3, HCC</kwd><kwd> CARM1</kwd><kwd> Bcl-2</kwd><kwd> Bax</kwd><kwd> Caspase-3</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>CARM1通过调控Bax/Bcl-2表达和Caspase-3活性进而调控肝癌生长作用<sup> </sup></title><p>刘美玲，洪宏海<sup>*</sup>，王征</p><p>广州医科大学附属第三医院检验科，广东 广州</p><p><img src="//html.hanspub.org/file/3-2150175x1_hanspub.png" /></p><p>收稿日期：2019年6月30日；录用日期：2019年7月19日；发布日期：2019年7月26日</p><disp-formula id="hanspub.31432-formula46"><graphic xlink:href="//html.hanspub.org/file/3-2150175x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：共激活因子相关精氨酸甲基转移酶1 (Coactivator-associated arginine methyltransferase 1, CARM1)在肝癌细胞中生长作用及机制研究。方法：qRT-PCR、western blot法检测肝癌细胞中CARM1表达；MTT法和台盼蓝实验检测肝癌细胞的生长情况；Caspase-3试剂盒检测Caspase-3活性；小分子干扰RNA干扰CARM1研究其作用和分子机制。结果：小分子干扰RNA明显敲低CARM1水平；干扰CARM1后明显抑制肝癌细胞生长，且下调抑凋亡蛋白Bcl-2和上调促凋亡蛋白Bax表达水平，同时激活Caspase-3活性。结论：CARM1通过调控Bax/Bcl-2表达和Caspase-3活性进而调控肝癌生长作用。</p><p>关键词 :肝癌，CARM1，Bcl-2，Bax，Caspase-3</p><disp-formula id="hanspub.31432-formula47"><graphic xlink:href="//html.hanspub.org/file/3-2150175x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-2150175x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-2150175x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>肿瘤的发生是由于促癌基因和抑癌基因的突变引起的。近些年发现，除促癌基因和抑癌基因的突变外，肿瘤表观遗传学也在肿瘤的发生发展中起着关键的作用 [<xref ref-type="bibr" rid="hanspub.31432-ref1">1</xref>]。DNA甲基化和共价组蛋白修饰是表观遗传调控的重要组成部分。研究发现肿瘤基因调控区高甲基化可促进肿瘤发生和发展 [<xref ref-type="bibr" rid="hanspub.31432-ref2">2</xref>]。因此，调控肿瘤表观遗传学的调控因子是潜在的肿瘤治疗靶点，目前几种DNA甲基转移酶和组蛋白脱乙酰基酶抑制剂已被批准用于癌症治疗 [<xref ref-type="bibr" rid="hanspub.31432-ref3">3</xref>]。共激活因子相关精氨酸甲基转移酶1 (Coactivator-associated arginine methyltransferase 1, CARM1) CARM1是一种重要的甲基转移酶，也称为精氨酸甲基酶4 (protein arginine methyltransferase 4, PRMT4)。最初发现CARM1和核受体辅助因子p160结合调控生物学功能 [<xref ref-type="bibr" rid="hanspub.31432-ref4">4</xref>]。后来研究发现CARM1与转录因子cAMP反应元件结合蛋白CBP、β-catenin和NF-κB的p65结合调控下游靶基因的转录 [<xref ref-type="bibr" rid="hanspub.31432-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.31432-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.31432-ref7">7</xref>]。很多研究表明CARM1在肿瘤的发生、发展和转移过程发挥着重要作用。文献报道CARM1促进乳腺癌、胰腺癌、骨肉瘤增殖和转移 [<xref ref-type="bibr" rid="hanspub.31432-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.31432-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.31432-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.31432-ref11">11</xref>]。在早期肝癌中，CARM1水平增高 [<xref ref-type="bibr" rid="hanspub.31432-ref12">12</xref>]。研究发现SKP2通过调控细胞核内的AMPK-SKP2-CARM1 信号通路诱导自噬并影响肝癌进展 [<xref ref-type="bibr" rid="hanspub.31432-ref13">13</xref>]。但是，CARM1在肝癌中直接作用尚不清楚。</p><p>在本篇论文中，我们采取小分子干扰片段抑制肝癌细胞中CARM1的表达，用MTT实验和台盼蓝实验检测肝癌的生长情况。同时检测相关凋亡蛋白Bax\Bcl-2和Caspase-3活性，初步阐明CARM1在肝癌中作用及分子机制。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 细胞培养</title><p>肝母细胞瘤细胞HepG2和肝癌细胞Huh7购自ATCC。用DMEM + 10%的胎牛血清完全培养基无菌于37˚、5% CO<sub>2</sub>的细胞培养箱中培养。</p></sec><sec id="s4_2"><title>2.2. 试剂和耗材</title><p>Caspase-3活性试剂盒购自Biovision公司。Real time PCR的SYBER Green和逆转录酶试剂盒购自Takara公司。RNA提取试剂盒购自康为世纪公司。siCARM1小分子干扰片段购自锐博公司。转染试剂Lipo2000购自Invtrogen公司。细胞培养液购Hyclone公司。细胞培养皿购自康宁公司。CARM1、Bax、Bcl-2、β-actin抗体购自CST公司。MTT和台盼蓝购自北京鼎国公司。</p></sec><sec id="s4_3"><title>2.3. 方法</title><p>MTT法检测HepG2和Huh7细胞增殖能力：采用噻唑兰颜色反应法，即MTT法进行细胞增殖活力的测定 [<xref ref-type="bibr" rid="hanspub.31432-ref14">14</xref>]。其原理为活细胞线粒体中的琥珀酸脱氢酶能使外源性MTT还原为水不溶性的蓝紫色晶体—甲缵(formazan)，并沉淀在细胞中，而死细胞无此功能。HepG2和Huh7细胞种植于96孔板，处理24h后，每孔加入10 &#181;l的MTT工作液(浓度为5 mg/ml)，继续培养4小时；加入三联溶液，培养箱中过夜以使蓝色结晶颗粒(甲缵)完全溶解，用酶标仪测定OD<sub>570</sub>的光密度值。实验中每份样品设3个复孔，实验至少重复3次。</p><p>台盼蓝法检测HepG2和Huh7细胞活力：台盼蓝能使死细胞染色，而不能使活细胞染色。HepG2和Huh7细胞种植于96孔板，处理24 h后，胰酶消化细胞，离心，重悬细胞，吸10 μl细胞悬液和10 μl 0.4%的台盼蓝溶液混合，充入细胞计数板，显微镜下计数四个大方格中染色和非染色细胞总数。非染色细胞除以非染色细胞和染色细胞的总数的百分数即细胞活力。</p><p>qRT-PCR实验</p><p>qRT-PCR检测CARM1的mRNA水平。具体实验如下：收集处理后的HepG2和Huh7细胞RNA，逆转录为cDNA，用Takara公司的SYBER green试剂盒进行实时荧光PCR实验。PCR条件为：95℃ 30 s，1个循环；PCR反应，95℃ 5 s，60℃ 15 s，45个循环；溶解，95℃ 0 s，65℃ 20 s，95℃ 0 s，1个循环。PCR结束后，根据反应得到的Cp值，使用相对定量的分析方法，以标准曲线进行校正，最后计算出样品中各mRNA的相对浓度。进行qRT-PCR引物序列如表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Real-time fluorescence quantitative PCR primer</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >NCBI ID</th><th align="center" valign="middle" >基因</th><th align="center" valign="middle" >引物</th><th align="center" valign="middle" >引物序列</th><th align="center" valign="middle" >产物大小</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >NM_199141.2</td><td align="center" valign="middle"  rowspan="2"  >CARM1</td><td align="center" valign="middle" >上游</td><td align="center" valign="middle" >5’-GAAGGAGATTTGCACAGGATAGA-3’</td><td align="center" valign="middle"  rowspan="2"  >125 bp</td></tr><tr><td align="center" valign="middle" >下游</td><td align="center" valign="middle" >5’-GACAGCCACACGGTCATTAT-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >NM_002046.5</td><td align="center" valign="middle"  rowspan="2"  >GAPDH</td><td align="center" valign="middle" >上游</td><td align="center" valign="middle" >5’-ACCATCTTCCAGGAGCGAGA-3’</td><td align="center" valign="middle"  rowspan="2"  >71 bp</td></tr><tr><td align="center" valign="middle" >下游</td><td align="center" valign="middle" >5’-GACTCCACGACGTACTCAGC-3’</td></tr></tbody></table></table-wrap><p>表1. 实时荧光定量PCR引物</p><p>CARM1干扰实验</p><p>CARM1干扰小分子片段购自锐博公司。</p><p>CARM1干扰实验具体方法如下：HepG2和Huh7细胞种植于六孔板中，待其融合度为50%~60%时候，用Lipo2000转染试剂转染CARM1干扰小分子片段，24小时后收集细胞RNA和蛋白，检测CARM1转录和蛋白水平。干扰CARM1小分子序列如表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> HE4 interference sequenc</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >基因</th><th align="center" valign="middle" >干扰片段</th><th align="center" valign="middle" >干扰序列</th></tr></thead><tr><td align="center" valign="middle" >CARM1</td><td align="center" valign="middle" >SiCARM1</td><td align="center" valign="middle" >5’-GCAAGCAGUCCUUCAUCAUCACUC-3’</td></tr></tbody></table></table-wrap><p>表2. HE4干扰序列</p><p>Caspase-3活性实验</p><p>5&#215;10<sup>6</sup> HepG2和Huh7细胞种植于6孔板中，干扰CARM1基因24 h后，将细胞重新悬浮在50 μl冷冻细胞溶解缓冲液中，冰上10分钟。在微型离心机(10,000 &#215; g)中离心1分钟。将上清液(细胞溶质提取物)转移到新鲜的试管中，然后放在冰上。测定蛋白质浓度，将50 μg~200 μg蛋白质稀释到50 μl，添加50 μl 2X反应缓冲液和5 μl的Devd PNA (200 μm终浓度)，在37˚培养1~2小时。分光光度计405 nm读数。</p><p>Western blot实验</p><p>Western blot [<xref ref-type="bibr" rid="hanspub.31432-ref15">15</xref>] 实验检测CARM1蛋白水平，具体实验方案如下：收集处理好的HepG2和Huh7细胞蛋白，进行蛋白定量，跑胶。加入CARM1一抗，4度过夜，收集一抗，加入二抗，然后加入ECL显色，拍照。</p></sec><sec id="s4_4"><title>2.4. 统计学分析</title><p>采用SPSS 17.0软件进行统计学处理。计量资料以均数&#177;标准差表示。采用t检验。P &lt; 0.05表示具有统计学意义。</p></sec></sec><sec id="s5"><title>3. 实验结果</title><sec id="s5_1"><title>3.1. 肝癌细胞中有效干扰CARM1基因</title><p>用小分子干扰片段siCARM1转染HepG2和Huh7细胞24小时后收集细胞RNA和蛋白。结果显示小分子干扰片段siCARM1明显敲低肝癌细胞的CARM1转录水平，沉默效果近80% (图1(A)和图1(C))。Western blot结果也显示小分子干扰片段siCARM1明显敲低CARM1蛋白水平(图1(B)和图1(D))，这些结果为进一步的功能实验提供基础。</p><p>图1. 小分子干扰片段siCARM1敲低CARM1水平效果</p></sec><sec id="s5_2"><title>3.2. 干扰CARM1后抑制HepG2和Huh7细胞生长</title><p>用小分子干扰片段siCARM1转染HepG2和Huh7细胞24小时后，MTT实验和台盼蓝实验检测HepG2和Huh7细胞的生长能力。MTT实验结果显示沉默CARM1后明显抑制HepG2和Huh7细胞的生长(图2(A)和图2(C))。台盼蓝实验也表明敲低CARM1后明显抑制HepG2和Huh7细胞的生长(图2(B)和图2(D))。这些结果提示CARM1调控肝癌细胞生长过程。</p><p>图2. 干扰CARM1后抑制HepG2和Huh7细胞生长</p></sec><sec id="s5_3"><title>3.3. CARM1调控肝癌细胞Bax和Bcl-2蛋白表达</title><p>为了阐明CARM1调控肝癌细胞生长作用分子机制，我们首先检测凋亡相关蛋白Bax和Bcl-2表达。结果显示，沉默CARM1后明显上调促凋亡蛋白Bax表达，抑制抑凋亡蛋白Bcl-2表达(图3(A)和图3(C))。同时，也明显上调Bax/Bcl-2比例(图3(B)和图3(D))。这些结果表明阻断CARM1后可能促进肝癌细胞凋亡过程进而抑制肝癌细胞的生长。</p><p>图3. CARM1调控肝癌细胞Bax和Bcl-2蛋白表达</p></sec><sec id="s5_4"><title>3.4. CARM1调控肝癌细胞Caspase-3活性</title><p>为了进一步阐明CARM1通过调控肝癌细胞凋亡进而影响肝癌细胞生长作用的分子机制，我们检测细胞凋亡过程关键酶Caspase-3活性。结果显示，干扰CARM1后，Caspase-3活性明显升高(图4(A)和图4(B))。以上结果表明，CARM1通过调控凋亡相关蛋白Bax/Bcl-2和Caspase-3活性进而调控肝癌的凋亡过程，从而抑制肝癌的生长。</p><p>图4. CARM1调控肝癌细胞Caspase-3活性</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>肝癌是一个全球性的健康问题，其发病率越来越高，死亡率也越来越高 [<xref ref-type="bibr" rid="hanspub.31432-ref16">16</xref>]。表观遗传的改变，如组蛋白修饰、DNA甲基化和小RNA介导过程，与多种癌症的增殖和转移密切相关 [<xref ref-type="bibr" rid="hanspub.31432-ref17">17</xref>]。越来越多证据表明肝癌和表观遗传改变有关 [<xref ref-type="bibr" rid="hanspub.31432-ref18">18</xref>]。共激活因子相关精氨酸甲基转移酶1 (Coactivator-associated arginine methyltransferase 1, CARM1)是蛋白质精氨酸甲基转移酶家族的一员，催化蛋白质底物中精氨酸(arg)残基甲基化，调控肿瘤表观遗传，进而改变基因转录过程 [<xref ref-type="bibr" rid="hanspub.31432-ref19">19</xref>]。在这篇文章中，我们采用小分子干扰RNA敲低CARM1水平，研究其在肝癌中作用及分子机制。我们发现敲低CARM1后抑制肝癌细胞的生长，促进凋亡蛋白Bax表达，抑制抑凋亡蛋白Bcl-2水平，同时促进Caspase-3活性，表明CARM1通过调控肝癌细胞的凋亡过程进而调控肝癌细胞生长。</p><p>除了异常分化和增殖外，细胞凋亡也是肿瘤的一个重要特征 [<xref ref-type="bibr" rid="hanspub.31432-ref20">20</xref>]。细胞凋亡主要由细胞凋亡蛋白Bcl-2家族调控。Bcl-2家族包括促凋亡蛋白Bak和Bax以及抑凋亡蛋白Bcl-2和Mcl-1 [<xref ref-type="bibr" rid="hanspub.31432-ref21">21</xref>]。文献报道许多肝癌中Bcl-2表达增高，抑制肝癌凋亡促进其增殖 [<xref ref-type="bibr" rid="hanspub.31432-ref22">22</xref>] ，同时Bcl-2高表达的病人比低表达病人的无病生存期明显缩短 [<xref ref-type="bibr" rid="hanspub.31432-ref23">23</xref>]。在我们实验中发现沉默CARM1后明显上调促凋亡蛋白Bax水平，下调抑凋亡蛋白Bcl-2水平，明显升高Bax/Bcl-2比例，表明阻断CARM1后促进肝癌细胞凋亡过程进而抑制肝癌细胞生长，后者被MTT实验和台盼蓝实验所证明。我们结果与其他文献报道阻断CARM1后抑制乳腺癌、骨肉瘤和胰腺癌生长作用类似 [<xref ref-type="bibr" rid="hanspub.31432-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.31432-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.31432-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.31432-ref11">11</xref>]。Caspase是调控细胞凋亡的重要酶。Caspase-3 (也称为cpp32、sca-1和cpp32b)是一种位于染色体4q34的casp-3基因编码的半胱氨酸蛋白酶 [<xref ref-type="bibr" rid="hanspub.31432-ref24">24</xref>] ，在细胞凋亡中起着关键作用，其可切割和激活Caspase-6、Caspase-7和Caspase-9。我们实验结果发现阻断CARM1后促进Caspase-3活性，进一步表明CARM1通过调控肝癌细胞凋亡过程进而调控肝癌的生长。但是，CARM1调控肝癌的Caspase-3活性的分子机制尚未清楚，还值得我们进一步研究，这块也是这篇文章不足之处。</p><p>总之，在这篇论文中我们研究调控甲基化关键酶CARM1在肝癌细胞生长中作用及机制。发现沉默CARM1后抑制肝癌细胞生长，进一步研究发现阻断CARM1后上调促凋亡蛋白Bax水平，下调抑凋亡蛋白Bcl-水平，且促进Caspase-3活性，这些结果表明CARM1通过调控细胞凋亡过程进而调控肝癌细胞生长，提示着CARM1可能成为肝癌治疗新的靶点，具有一定的临床意义。</p></sec><sec id="s7"><title>基金项目</title><p>广州医科大学博士启动基金(项目编号：2015C24)；广州市卫生局一般引导项目(项目编号：20171A011312)；广州市卫生局中西医结合项目(项目编号：20182A011020)广州医科大学大学生实验室开放项目(项目编号：B185004039)；广东省教育厅项目(项目编号：2017KTSCX155)；广东省自然科学基金(项目编号：2018A030310298)。</p></sec><sec id="s8"><title>文章引用</title><p>刘美玲,洪宏海,王 征. CARM1通过调控Bax/Bcl-2表达和Caspase-3活性进而调控肝癌生长作用CARM1 Regulates the Growth of Hepatocellular Carcinoma Cells via Regulation of Bax/Bcl-2 Level and Caspase-3 Activity[J]. 世界肿瘤研究, 2019, 09(03): 90-97. https://doi.org/10.12677/WJCR.2019.93013</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31432-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rodriguez-Paredes, M. and Esteller, M. (2011) Cancer Epigenetics Reaches Mainstream Oncology. Nature Medicine, 17, 330-339. https://doi.org/10.1038/nm.2305</mixed-citation></ref><ref id="hanspub.31432-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Fraga, M.F., et al. (2005) Loss of Acetylation at Lys16 and Trimethylation at Lys20 of Histone H4 Is a Common Hallmark of Human Cancer. Nature Genetics, 37, 391-400. https://doi.org/10.1038/ng1531</mixed-citation></ref><ref id="hanspub.31432-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kelly, T.K., De Carvalho, D.D. and Jones, P.A. (2010) Epigenetic Modifications as Therapeutic Targets. Nature Biotechnology, 28, 1069-1078. https://doi.org/10.1038/nbt.1678</mixed-citation></ref><ref id="hanspub.31432-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Suzuki, S., et al. (2004) Specific Differences in Gene Expression Profile Revealed by cDNA Microarray Analysis of Glutathione S-Transferase Placental form (GST-P) Immunohistochemically Positive Rat Liver Foci and Surrounding Tissue. Carcinogenesis, 25, 439-443. https://doi.org/10.1093/carcin/bgh030</mixed-citation></ref><ref id="hanspub.31432-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Xu, W., et al. (2001) A Transcriptional Switch Mediated by Cofactor Methylation. Science, 294, 2507-2511.  
https://doi.org/10.1126/science.1065961</mixed-citation></ref><ref id="hanspub.31432-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Koh, S.S., et al. (2002) Synergistic Coactivator Function by Coactivator-Associated Arginine Methyltransferase (CARM) 1 and β-Catenin with Two Different Classes of DNA-Binding Transcriptional Activators. The Journal of Biological Chemistry, 277, 26031-26035. https://doi.org/10.1074/jbc.M110865200</mixed-citation></ref><ref id="hanspub.31432-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Covic, M., et al. (2005) Arginine Methyltransferase CARM1 Is a Promoter-Specific Regulator of NF-κB-Dependent Gene Expression. The EMBO Journal, 24, 85-96. https://doi.org/10.1038/sj.emboj.7600500</mixed-citation></ref><ref id="hanspub.31432-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y.P., et al. (2016) Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer. Molecular Cell, 64, 673-687. https://doi.org/10.1016/j.molcel.2016.09.028</mixed-citation></ref><ref id="hanspub.31432-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Frietze, S., et al. (2008) CARM1 Regulates Estrogen-Stimulated Breast Cancer Growth through Up-Regulation of E2F1. Cancer Research, 68, 301-306. https://doi.org/10.1158/0008-5472.CAN-07-1983</mixed-citation></ref><ref id="hanspub.31432-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., et al. (2016) CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis. Cancer Cell, 30, 179-180. https://doi.org/10.1016/j.ccell.2016.06.013</mixed-citation></ref><ref id="hanspub.31432-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Li, S., et al. (2017) The Overexpression of CARM1 Promotes Human Osteosarcoma Cell Proliferation through the pGSK3β/β-Catenin/CyclinD1 Signaling Pathway. International Journal of Biological Sciences, 13, 976-984.  
https://doi.org/10.7150/ijbs.19191</mixed-citation></ref><ref id="hanspub.31432-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Osada, S., et al. (2006) Altered Gene Expression of Transcriptional Regulatory Factors in Tumor Marker-Positive Cells during Chemically Induced Hepatocarcinogenesis. Toxicology Letters, 167, 106-113.  
https://doi.org/10.1016/j.toxlet.2006.08.014</mixed-citation></ref><ref id="hanspub.31432-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wei, X., et al. (2018) SKP2 Promotes Hepatocellular Carcinoma Progression through Nuclear AMPK-SKP2-CARM1 Signaling Transcriptionally Regulating Nutrient-Deprived Autophagy Induction. Cellular Physiology and Biochemistry, 47, 2484-2497. https://doi.org/10.1159/000491622</mixed-citation></ref><ref id="hanspub.31432-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Stockert, J.C., et al. (2012) MTT Assay for Cell Viability: Intracellular Localization of the Formazan Product Is in Lipid Droplets. Acta Histochemica, 114, 785-796. https://doi.org/10.1016/j.acthis.2012.01.006</mixed-citation></ref><ref id="hanspub.31432-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Jian, W., et al. (2019) A Novel Role of HuR in Epigallocatechin-3-Gallate (EGCG) Induces Tumour Cells Apoptosis. Journal of Cellular and Molecular Medicine, 23, 3767-3771. https://doi.org/10.1111/jcmm.14249</mixed-citation></ref><ref id="hanspub.31432-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Llovet, J.M., Burroughs, A. and Bruix, J. (2003) Hepatocellular Carcinoma. The Lancet, 362, 1907-1917.  
https://doi.org/10.1016/S0140-6736(03)14964-1</mixed-citation></ref><ref id="hanspub.31432-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Han, T.S., et al. (2018) The Epigenetic Regulation of HCC Metastasis. International Journal of Molecular Sciences, 19, 3978. https://doi.org/10.3390/ijms19123978</mixed-citation></ref><ref id="hanspub.31432-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Khan, F.S., et al. (2017) Epigenetic Mechanisms Regulating the Development of Hepatocellular Carcinoma and Their Promise for Therapeutics. Hepatology International, 11, 45-53. https://doi.org/10.1007/s12072-016-9743-4</mixed-citation></ref><ref id="hanspub.31432-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bedford, M.T. and Clarke, S.G. (2009) Protein Arginine Methylation in Mammals: Who, What, and Why. Molecular Cell, 33, 1-13. https://doi.org/10.1016/j.molcel.2008.12.013</mixed-citation></ref><ref id="hanspub.31432-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Su, Z., et al. (2015) Apoptosis, Autophagy, Necroptosis, and Cancer Metastasis. Molecular Cancer, 14, 48.  
https://doi.org/10.1186/s12943-015-0321-5</mixed-citation></ref><ref id="hanspub.31432-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Adams, J.M. and Cory, S. (2007) The Bcl-2 Apoptotic Switch in Cancer Development and Therapy. Oncogene, 26, 1324-1337. https://doi.org/10.1038/sj.onc.1210220</mixed-citation></ref><ref id="hanspub.31432-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Shigematsu, S., et al. (2011) ZNF689 Suppresses Apoptosis of Hepatocellular Carcinoma Cells through the Down-Regulation of Bcl-2 Family Members. Experimental Cell Research, 317, 1851-1859.  
https://doi.org/10.1016/j.yexcr.2011.05.012</mixed-citation></ref><ref id="hanspub.31432-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Brito, A.F., et al. (2016) Targeting Hepatocellular Carcinoma: What Did We Discover So Far? Oncology Reviews, 10, 302. https://doi.org/10.4081/oncol.2016.302</mixed-citation></ref><ref id="hanspub.31432-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Khalilzadeh, B., et al. (2018) Advances in Nanomaterial Based Optical Biosensing and Bioimaging of Apoptosis via Caspase-3 Activity: A Review. Microchimica Acta, 185, 434. https://doi.org/10.1007/s00604-018-2980-6</mixed-citation></ref></ref-list></back></article>